Syndax Announces Participation at Upcoming Investor Conferences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) announced participation in several upcoming investor conferences. Key events include a fireside chat at the Citi 2023 Virtual Oncology Leadership Summit on February 21, a session at Cowen's 43rd Annual Healthcare Conference on March 6, a panel discussion on leukemia at the same conference on March 8, and another fireside chat at Barclays Global Healthcare Conference on March 15. Live webcasts of these discussions will be accessible via the Company’s investor website, where replays will also be available for a limited time. Syndax is focused on developing innovative cancer therapies, with key candidates currently in pivotal trials.
Details
News Market Reaction – SNDX
The recorded move for SNDX in the trading session of this news was +1.86%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Feb. 14, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in the upcoming investor conferences:
- A fireside chat at the Citi 2023 Virtual Oncology Leadership Summit at 2:00 p.m. ET on Tuesday, February 21, 2023
- A fireside chat at Cowen's 43rd Annual Healthcare Conference at 9:10 a.m. ET on Monday, March 6, 2023 in Boston, MA
- A panel discussion on leukemia at Cowen's 43rd Annual Healthcare Conference at 12:50 p.m. ET on Wednesday, March 8, 2023 in Boston, MA
- A fireside chat at the Barclays Global Healthcare Conference at 10:45 a.m. ET on Wednesday, March 15, 2023 in Miami, FL
A live webcast of the fireside chats can be accessed from the Investor section of the Company's website at www.syndax.com, where a replay of the events will also be available for a limited time.
About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib, a highly selective inhibitor of the Menin–KMT2A binding interaction, and axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, both currently in pivotal trials. For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn.
Syndax Contacts
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
View original content:https://www.prnewswire.com/news-releases/syndax-announces-participation-at-upcoming-investor-conferences-301745697.html
SOURCE Syndax Pharmaceuticals, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.